The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
Authors
Keywords
-
Journal
ONCOGENE
Volume 37, Issue 14, Pages 1830-1844
Publisher
Springer Nature
Online
2018-01-18
DOI
10.1038/s41388-017-0111-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathways and mechanisms of venetoclax resistance
- (2017) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
- (2016) Sina Oppermann et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
- (2016) Andrew R. Conery et al. CANCER RESEARCH
- Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation
- (2016) Monika Anna Grygorowicz et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
- (2016) X. Niu et al. CLINICAL CANCER RESEARCH
- Bromodomain 4: a cellular Swiss army knife
- (2016) Ballachanda N. Devaiah et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Malignant hematopoietic cell lines:in vitromodels for double-hit B-cell lymphomas
- (2016) Hans G. Drexler et al. LEUKEMIA & LYMPHOMA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
- (2015) L Li et al. LEUKEMIA
- ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells
- (2015) Nadine Johnson-Farley et al. LEUKEMIA & LYMPHOMA
- MYC Alterations in Diffuse Large B-Cell Lymphomas
- (2015) Kennosuke Karube et al. SEMINARS IN HEMATOLOGY
- Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
- (2015) Matthew B. Siegel et al. Oncotarget
- Aggressive B-Cell Lymphomas With Translocations Involving BCL6 and MYC Have Distinct Clinical-Pathologic Characteristics
- (2014) Samir K. Turakhia et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
- (2014) A Moros et al. LEUKEMIA
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
- (2013) Shaoying Li et al. ADVANCES IN ANATOMIC PATHOLOGY
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability
- (2013) Bryan King et al. CELL
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Aberrant epigenetic regulation of bromodomain Brd4 in human colon cancer
- (2011) R. M. Rodriguez et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
- (2010) Matija Snuderl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78
- (2010) G. Roue et al. BLOOD
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma
- (2010) G. Fan et al. BLOOD
- Double-hit B-cell lymphomas
- (2010) S. M. Aukema et al. BLOOD
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search